Alan Myers Selected Research

Lymphoma (Lymphomas)

1/2016

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alan Myers Research Topics

Disease

2	Mucositis 06/2017 - 01/2016
2	Neoplasms (Cancer) 06/2017 - 01/2016
2	Dermatitis 06/2017 - 01/2016
1	Infections 10/2019
1	Hodgkin Disease (Hodgkin's Disease) 01/2018
1	Lymphoma (Lymphomas) 01/2016

Drug/Important Bio-Agent (IBA)

2	Busulfan (Busulfex)FDA Link 01/2018 - 06/2017
2	Gemcitabine FDA Link 01/2018 - 06/2017
2	Melphalan (Alkeran)FDA LinkGeneric 01/2018 - 06/2017
1	efavirenz (Sustiva)FDA Link 10/2019
1	Reverse Transcriptase InhibitorsIBA 10/2019
1	Transaminases (Aminotransferases)IBA 06/2017
1	Vorinostat FDA Link 01/2016
1	Rituximab (Mabthera)FDA Link 01/2016
1	Azacitidine (5 Azacytidine)FDA Link 01/2016
1	DNA (Deoxyribonucleic Acid)IBA 01/2016
1	AntigensIBA 01/2016
1	MethyltransferasesIBA 01/2016

Therapy/Procedure

1	Therapeutics 01/2018
1	Stem Cell Transplantation 01/2018
1	Drug Therapy (Chemotherapy) 01/2016